137.03
0.29 (0.21%)
| Previous Close | 136.74 |
| Open | 137.30 |
| Volume | 1,178,252 |
| Avg. Volume (3M) | 897,431 |
| Market Cap | 13,590,842,368 |
| Price / Earnings (TTM) | 40.54 |
| Price / Earnings (Forward) | 26.81 |
| Price / Sales | 5.81 |
| Price / Book | 5.23 |
| 52 Weeks Range | |
| Earnings Date | 30 Oct 2025 |
| Profit Margin | 12.68% |
| Operating Margin (TTM) | 4.14% |
| Diluted EPS (TTM) | 2.95 |
| Quarterly Revenue Growth (YOY) | 11.10% |
| Quarterly Earnings Growth (YOY) | -81.80% |
| Total Debt/Equity (MRQ) | 19.45% |
| Current Ratio (MRQ) | 3.13 |
| Operating Cash Flow (TTM) | 529.90 M |
| Levered Free Cash Flow (TTM) | 235.48 M |
| Return on Assets (TTM) | 8.75% |
| Return on Equity (TTM) | 12.43% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Bullish | Mixed |
| Drug Manufacturers - Specialty & Generic (Global) | Bullish | Mixed | |
| Stock | Neurocrine Biosciences, Inc. | Bullish | Mixed |
AIStockmoo Score
| Analyst Consensus | 4.0 |
| Insider Activity | NA |
| Price Volatility | 2.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | -1.5 |
| Average | 0.50 |
|
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Mid Core |
| % Held by Insiders | 1.06% |
| % Held by Institutions | 98.86% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 182.00 (Goldman Sachs, 32.82%) | Buy |
| Median | 170.00 (24.06%) | |
| Low | 141.00 (Wedbush, 2.90%) | Buy |
| Average | 164.64 (20.15%) | |
| Total | 10 Buy, 1 Hold | |
| Avg. Price @ Call | 134.26 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Needham | 22 Sep 2025 | 170.00 (24.06%) | Buy | 146.62 |
| Morgan Stanley | 05 Sep 2025 | 163.00 (18.95%) | Buy | 144.10 |
| 31 Jul 2025 | 158.00 (15.30%) | Buy | 128.23 | |
| RBC Capital | 05 Sep 2025 | 149.00 (8.74%) | Buy | 144.10 |
| 31 Jul 2025 | 144.00 (5.09%) | Buy | 128.23 | |
| Guggenheim | 01 Aug 2025 | 175.00 (27.71%) | Buy | 128.91 |
| JP Morgan | 31 Jul 2025 | 145.00 (5.82%) | Hold | 128.23 |
| Piper Sandler | 31 Jul 2025 | 175.00 (27.71%) | Buy | 128.23 |
| Stifel | 31 Jul 2025 | 174.00 (26.98%) | Buy | 128.23 |
| Wedbush | 31 Jul 2025 | 141.00 (2.90%) | Buy | 128.23 |
| Truist Securities | 21 Jul 2025 | 163.00 (18.95%) | Buy | 131.83 |
| Goldman Sachs | 10 Jul 2025 | 182.00 (32.82%) | Buy | 134.92 |
| UBS | 09 Jul 2025 | 174.00 (26.98%) | Buy | 133.51 |
| Show more | ||||
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |